/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | CNSPCNS Pharmaceuticals, |
|---|---|
| Last close | $4.55close 2026-11-03 |
| Change % | +3.64%close 2026-11-03 |
| Market cap | $7Mclose 2026-11-03 |
| P/E | loss, no P/E |
| Revenue | no revenue filed |
| Rev growth (YoY) | no revenue filed |
| Net income | $-15987⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 FilingDEF 14A · 0001683168-26-006660 · filed 2026-08-21 Open the filing on EDGAR →Open the XBRL payload →CiteCNS Pharmaceuticals, Inc. (CNSP), us-gaap:NetIncomeLoss: -15,987 USD, fiscal year ended 2025-12-31. Form DEF 14A, accession 0001683168-26-006660, filed 2026-08-21. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001729427/us-gaap/NetIncomeLoss.json |
| Net margin | not filed |
| EPS (diluted) | $-35.75⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-12-31 Filing10-K · 0001683168-26-002550 · filed 2026-03-31 Open the filing on EDGAR →Open the XBRL payload →CiteCNS Pharmaceuticals, Inc. (CNSP), us-gaap:EarningsPerShareDiluted: -35.75 USD per share, fiscal year ended 2025-12-31. Form 10-K, accession 0001683168-26-002550, filed 2026-03-31. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001729427/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | not scored |
| Altman Z-ScoreUNVALIDATED | not scored |
| Beneish M-ScoreUNVALIDATED | not scored |
| Next earnings | rep. 05-16 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.